Morrison Foerster is an international law firm with lawyers practicing throughout the United States, Asia, and Europe. Click to discover more.

mofo_share_image.jpg

Morrison Foerster

favicon.ico

favicon-16x16.png

favicon-32x32.png

apple-touch-icon.png

MoFo Favicons

Terms / Notices

Cookies

Privacy Policy

Attorney Advertising

Secure Login

Alumni

  Facebook

MoFo Facebook

  Linkedin

MoFo LinkedIN

Twitter

MoFo Twitter

YouTube

MoFo Youtube

Morrison Foerster - Footer

You have not solved the recaptcha challenge yet or session expired, try again.

Disclaimer

Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our <a href="https://www.mofo.com/about/privacy-policy.html">Privacy Policy</a>, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.

Feedback

mofo-logo-2022.svg

People

Capabilities

Resources

About

Culture

Offices

Careers

Stay Connected

Bethany Hills spoke to Medtech Insight for its coverage of Bodysphere’s retracted announcement of its emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a COVID-19 serologic test, which Bethany says should serve as a cautionary tale to other medtech companies.

Bodysphere EUA Blunder is a Lesson in What Not To Do

Coronavirus Box Element Module [redesign]

About Morrison Forester

people-default-header-desktop.jpg

people-default-header-mobile.jpg

Default Meta Data

Bethany Hills spoke to Medtech Insight for its coverage of Bodysphere’s retracted announcement of its emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a COVID-19 serologic test, which Bethany says should serve as a cautionary tale to other medtech companies.“Do not release any press releases until you have the EUA letter in hand,” Bethany said. “The second you have it you can release every press release you want, and the FDA will put up the announcement on their website in a few hours.”Read the <a href="https://medtech.pharmaintelligence.informa.com/MT126522/Bodysphere-EUA-Blunder-Is-A-Lesson-In-What-Not-To-Do" target="_blank">full article</a> (subscription required).

Bodysphere EUA Blunder is a Lesson in What Not To Do

Sign Up

FDA Regulatory + Life Sciences Compliance